CoChat
Sign Up
Cited by 59Diabetes and associated disordersDiabetes Management and ResearchT-cell and B-cell Immunology

Anti-CD3 antibodies for type 1 diabetes: beyond expectations

Bach, Jean-François·2011·The Lancet
DOI 10.1016/s0140-6736(11)60980-x
Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(11)60980-x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • After promising phase 1-2 trials in patients with recent-onset type 1 diabetes and detectable endogenous insulin production, phase 3 trials of anti-CD3 antibodies (otelixizumab and teplizumab), and the Diamyd vaccine (GAD-alum immunotherapy) did not meet primary endpoints.

    “Disappointingly, after promising phase 1–2 trials in patients with recent-onset type 1 diabetes and detectable endogenous insulin production, phase 3 trials of anti-CD3 antibodies (otelixizumab and teplizumab), and the Diamyd vaccine (GAD-alum immunotherapy) did not meet primary endpoints.135–141”

    From Type 1 diabetes (2014) · cites this paper as [139]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bach, J.-F.
Affiliations
Hôpital Necker-Enfants Malades (FR)
Corresponding author
Bach, Jean-François
ORCID
Bach, Jean-François
Venue
The Lancet
Publisher
Elsevier BV
Published
2011-08
Volume
378
Issue
9790
Pages
459-460
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(11)60980-x
OpenAlex
W2034790724
Cited by
59
References
3
Citations by year
2024: 4 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 2 · 2018: 1 · 2017: 5 · 2016: 3 · 2015: 7 · 2014: 4 · 2013: 12 · 2012: 12
FWCI
6.20
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
type 1 diabetes, anti-CD3 antibody, teplizumab, immunotherapy, cyclosporine, beta-cell function, C-peptide, glycemic control, insulin dose reduction, disease progression prevention, children and young adults
MeSH terms
Antibodies, Monoclonal, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Hypoglycemic Agents, Time Factors, Randomized Controlled Trials as Topic, Muromonab-CD3, Treatment Outcome, CD3 Complex, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review